福安药业11月17日获融资买入1244.91万元，融资余额4.03亿元

Core Viewpoint - Fu'an Pharmaceutical experienced a decline of 1.27% in stock price on November 17, with a trading volume of 117 million yuan, indicating a challenging market environment for the company [1] Financing Summary - On November 17, Fu'an Pharmaceutical had a financing buy-in amount of 12.45 million yuan and a financing repayment of 16.83 million yuan, resulting in a net financing outflow of 4.38 million yuan [1] - The total financing and securities balance for Fu'an Pharmaceutical as of November 17 is 403 million yuan, which accounts for 7.24% of its circulating market value, indicating a high level of financing compared to the past year [1] - The company had no short-selling activity on November 17, with a short-selling balance of 0 shares, reflecting a low level of short interest [1] Business Performance Summary - As of October 31, Fu'an Pharmaceutical had 39,200 shareholders, an increase of 0.72% from the previous period, while the average circulating shares per person decreased by 0.71% to 24,700 shares [2] - For the period from January to September 2025, Fu'an Pharmaceutical reported a revenue of 1.315 billion yuan, a year-on-year decrease of 34.08%, and a net profit attributable to shareholders of 166 million yuan, down 44.87% year-on-year [2] - Since its A-share listing, Fu'an Pharmaceutical has distributed a total of 688 million yuan in dividends, with 202 million yuan distributed over the past three years [2] Shareholding Summary - As of September 30, 2025, Hong Kong Central Clearing Limited was the eighth largest circulating shareholder of Fu'an Pharmaceutical, holding 4.9804 million shares, which is a decrease of 470,000 shares from the previous period [2]